MedPath

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.eortc.be

Follow-up in Early and Locally Advanced Breast Cancer Patients

Active, not recruiting
Conditions
Breast Cancer
First Posted Date
2019-03-01
Last Posted Date
2024-01-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
830
Registration Number
NCT03859453
Locations
🇪🇸

Hospital Universitario Reina Sofia, Córdoba, Spain

🇩🇪

Universitaetsklinikum Leipzig-Klinik fuer Strahlentherapie und Radioonkologie, Leipzig, Germany

🇧🇪

C.H.U. Sart-Tilman, Liège, Belgium

and more 25 locations

E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Recruiting
Conditions
Cancer
First Posted Date
2019-01-28
Last Posted Date
2025-03-21
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
2000
Registration Number
NCT03818503
Locations
🇫🇷

Clinique Pasteur-Lanroze (1174), Brest, France

🇦🇹

Medical University of Graz - Radio-oncology, Graz, Austria

🇦🇹

Ordensklinikum Linz-Barmherzige Schwestern, Linz, Austria

and more 74 locations

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Phase 2
Withdrawn
Conditions
Hepatobiliary Neoplasm
GastroEsophageal Cancer
Esophageal Cancer
Biliary Tract Cancer
Interventions
First Posted Date
2019-01-28
Last Posted Date
2020-02-05
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT03818997

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

Completed
Conditions
Glioblastoma
First Posted Date
2018-12-10
Last Posted Date
2024-03-08
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
599
Registration Number
NCT03770468
Locations
🇫🇷

CHRU de Lille, Lille, France

🇫🇷

Hopitaux de Marseille - Hôpital de La Timone (APHM), Marseille, France

🇩🇪

Technische Universitaet Muenchen - Klinikum Rechts Der Isar, Muenchen, Germany

and more 24 locations

Trial in Low Grade Glioma Patients: Wait or Treat

Phase 3
Terminated
Conditions
Wait or Treat
Low-grade Glioma
Temozolomide
Phase III
Interventions
Radiation: Radiotherapy
Procedure: Surgery
First Posted Date
2018-12-04
Last Posted Date
2022-02-01
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
19
Registration Number
NCT03763422
Locations
🇬🇧

Clatterbridge Centre for Oncology NHS Trust - Clatterbridge NHS -Wirral, Wirral, United Kingdom

🇦🇺

Prince of Wales Hospital, Randwick - Sydney, New South Wales, Australia

🇫🇷

CHRU de Lille, Lille, France

and more 42 locations

Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC

Phase 3
Withdrawn
Conditions
Squamous Cell Head and Neck Carcinoma
Interventions
Radiation: radiotherapy
Drug: Placebo
First Posted Date
2018-09-17
Last Posted Date
2021-05-10
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT03673735

Reduced Dose-density of Denosumab for Unresectable GCTB

Phase 2
Terminated
Conditions
Bone Giant Cell Tumor
Interventions
First Posted Date
2018-08-08
Last Posted Date
2021-01-06
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
2
Registration Number
NCT03620149
Locations
🇪🇸

Hospital De La Santa Creu I Sant Pau, Barcelona, Spain

🇪🇸

Hospital Universitario San Carlos, Madrid, Spain

🇬🇧

Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom

and more 5 locations

Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer Stage II
Breast Cancer Stage III
Interventions
Drug: doxorubicin/cyclophosphamide
Drug: epirubicin/cyclophosphamide
First Posted Date
2018-08-01
Last Posted Date
2024-01-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
366
Registration Number
NCT03609047
Locations
🇧🇪

Heilig Hartziekenhuis Lier, Lier, Belgium

🇵🇱

Medical University Of Gdansk, Gdansk, Poland

🇵🇹

Centro Hospitalar do Porto-- Hospital de Santo Antonio, Porto, Portugal

and more 70 locations

Study of Photopheresis in the Treatment of Erythrodermic MF and SS

Phase 2
Withdrawn
Conditions
Lymphoma, T-Cell, Cutaneous
Mycosis Fungoides/Sezary Syndrome
Interventions
Device: THERAKOS CELLEX Photopheresis System
First Posted Date
2018-06-20
Last Posted Date
2021-09-08
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT03563040
Locations
🇨🇭

UniversitaetsSpital Zurich - Division of Dermatology, Zürich, Switzerland

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Phase 2
Active, not recruiting
Conditions
Advanced Hodgkin Lymphoma
Interventions
First Posted Date
2018-05-07
Last Posted Date
2023-11-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
150
Registration Number
NCT03517137
Locations
🇳🇱

Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands

🇳🇱

Erasmus MC, Rotterdam, Netherlands

🇵🇱

Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland

and more 13 locations
© Copyright 2025. All Rights Reserved by MedPath